Send us Feedback

Novartis AG (NVS)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

NVS » Topics » Note: All growth figures refer to year-to-date worldwide sales growth in local currencies

This excerpt taken from the NVS 6-K filed Jul 19, 2007.

Note: All growth figures refer to year-to-date worldwide sales growth in local currencies

 

Novartis has received seven major new regulatory approvals for pharmaceuticals in the US and Europe since the start of 2007, making significant progress in delivering a wave of new medicines – many with “first-in-class” status addressing significant medical needs.

 

These include the approval and launch of the high blood pressure medicine Tekturna/Rasilez in the US, with a launch in Europe anticipated soon. Exforge was launched in the US – three months ahead of schedule – and also in Europe. Others approved and launched in the first half were Aclasta/Reclast in the US for Paget’s disease, the blindness therapy Lucentis in Europe and Sebivo in Europe and China for hepatitis B. Exelon Patch won US approval in July as the first skin patch therapy for Alzheimer’s disease and Parkinson’s disease dementia.

 

A review of the leading marketed pharmaceutical products follows:

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki